دورية أكاديمية
أعرض في EDS

Neurocognitive status and risk of mortality among people living with human immunodeficiency virus: an 18-year retrospective cohort study.

التفاصيل البيبلوغرافية
العنوان: Neurocognitive status and risk of mortality among people living with human immunodeficiency virus: an 18-year retrospective cohort study.
المؤلفون: Naveed Z; Department of Epidemiology, College of Public Health, University of Nebraska Medical Center, 984355 Medical Center, Omaha, NE, 68198-4395, USA., Fox HS; Department of Neurological Sciences, University of Nebraska Medical Center, Omaha, NE, USA., Wichman CS; Department of Biostatistics, University of Nebraska Medical Center, Omaha, NE, USA., Alam M; Department of Biostatistics, University of Nebraska Medical Center, Omaha, NE, USA., May P; Department of Neurological Sciences, University of Nebraska Medical Center, Omaha, NE, USA., Arcari CM; Department of Epidemiology, College of Public Health, University of Nebraska Medical Center, 984355 Medical Center, Omaha, NE, 68198-4395, USA., Meza J; Department of Biostatistics, University of Nebraska Medical Center, Omaha, NE, USA., Totusek S; Department of Neurological Sciences, University of Nebraska Medical Center, Omaha, NE, USA., Baccaglini L; Department of Epidemiology, College of Public Health, University of Nebraska Medical Center, 984355 Medical Center, Omaha, NE, 68198-4395, USA. lorena.baccaglini@unmc.edu.
المصدر: Scientific reports [Sci Rep] 2021 Feb 12; Vol. 11 (1), pp. 3738. Date of Electronic Publication: 2021 Feb 12.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : Nature Publishing Group, copyright 2011-
مواضيع طبية MeSH: Cognitive Dysfunction/*mortality , Cognitive Dysfunction/*physiopathology , HIV Infections/*mortality, Adult ; Anti-Retroviral Agents/therapeutic use ; Cognition/physiology ; Cognitive Dysfunction/virology ; Cohort Studies ; Databases, Factual ; Executive Function/physiology ; Female ; HIV/metabolism ; HIV/pathogenicity ; HIV Infections/drug therapy ; HIV Infections/physiopathology ; Humans ; Male ; Middle Aged ; Neurocognitive Disorders/mortality ; Neurocognitive Disorders/physiopathology ; Neurocognitive Disorders/virology ; Proportional Hazards Models ; Retrospective Studies ; Risk Factors ; United States/epidemiology
مستخلص: HIV-related neurocognitive impairment (NCI) may increase the risk of death. However, a survival disadvantage for patients with NCI has not been well studied in the post-combination antiretroviral therapy (cART) era. Specifically, limited research has been conducted considering the reversible nature and variable progression of the impairment and this area demands further evaluation. We performed multivariable Cox proportional hazards modeling to assess the association between baseline NCI (global T scores) and mortality. A joint modeling approach was then used to model the trajectory of global neurocognitive functioning over time and the association between neurocognitive trajectory and mortality. Among the National NeuroAIDS Tissue Consortium's (NNTC) HIV-infected participants, we found a strong negative association between NCI and mortality in the older age groups (e.g., at age = 55, HR = 0.79; 95% CI 0.64-0.99). Three neurocognitive sub-domains (abstraction and executive functioning, speed of information processing, and motor) had the strongest negative association with mortality. Joint modelling indicated a 33% lower hazard for every 10-unit increase in global T scores (HR = 0.67; 95% CI 0.56-0.80). The study identified older HIV-infected individuals with NCI as a group needing special attention for the longevity of life. The study has considerable prognostic utility by not only predicting mortality hazard, but also future cognitive status.
References: Clin Infect Dis. 2011 Jan 15;52(2):235-43. (PMID: 21288850)
J Neuroimmune Pharmacol. 2013 Dec;8(5):1087-97. (PMID: 24259252)
Top HIV Med. 2010 Apr-May;18(2):45-55. (PMID: 20516524)
J Neuroimmune Pharmacol. 2010 Sep;5(3):294-309. (PMID: 20396973)
J Neurovirol. 2012 Aug;18(4):264-76. (PMID: 22528476)
Exp Ther Med. 2012 Oct;4(4):665-668. (PMID: 23170123)
J Neuroimmunol. 2004 Dec;157(1-2):3-10. (PMID: 15579274)
J Neurovirol. 2011 Apr;17(2):176-83. (PMID: 21416169)
Circulation. 2008 Jul 8;118(2):e29-35. (PMID: 18566319)
JAMA. 2008 Jul 2;300(1):51-9. (PMID: 18594040)
J Clin Exp Neuropsychol. 2011 Aug;33(7):793-804. (PMID: 21547817)
AIDS. 2012 Jun 19;26(10):1205-13. (PMID: 22706007)
AIDS Behav. 2018 Oct;22(10):3198-3208. (PMID: 29705930)
J Clin Exp Neuropsychol. 2004 Sep;26(6):759-78. (PMID: 15370374)
Nat Rev Neurol. 2016 Apr;12(4):234-48. (PMID: 26965674)
J Neurovirol. 2011 Feb;17(1):3-16. (PMID: 21174240)
Neuropsychology. 2018 Nov;32(8):966-972. (PMID: 30211610)
J Neurovirol. 2003 Apr;9(2):222-7. (PMID: 12707852)
PLoS One. 2017 Oct 5;12(10):e0185352. (PMID: 28981535)
BMC Infect Dis. 2019 Feb 15;19(1):169. (PMID: 30770728)
Am J Public Health. 2009 Apr;99 Suppl 1:S118-23. (PMID: 19218183)
Am J Epidemiol. 2016 Jul 1;184(1):67-77. (PMID: 27188943)
Neurology. 2007 Oct 30;69(18):1789-99. (PMID: 17914061)
Am J Geriatr Psychiatry. 2009 Apr;17(4):281-90. (PMID: 19307857)
J Neurol Sci. 2007 Sep 15;260(1-2):11-5. (PMID: 17482212)
Psychol Aging. 2008 Sep;23(3):595-607. (PMID: 18808249)
AIDS. 2017 Oct 23;31(16):2217-2225. (PMID: 28742529)
J Acquir Immune Defic Syndr. 2005 Oct 1;40(2):212-8. (PMID: 16186740)
Neuropathol Appl Neurobiol. 2001 Aug;27(4):326-35. (PMID: 11532163)
Alzheimers Res Ther. 2015 Apr 06;7(1):37. (PMID: 25848401)
Neurology. 2009 Apr 28;72(17):1465-72. (PMID: 19398702)
Neurology. 1993 Jan;43(1):176-82. (PMID: 8093809)
AIDS Behav. 2018 Apr;22(4):1341-1351. (PMID: 28887669)
Clin Infect Dis. 2013 Apr;56(7):1004-17. (PMID: 23175555)
Public Health Rep. 2015 Sep-Oct;130(5):505-13. (PMID: 26327728)
Neurology. 2010 Dec 7;75(23):2087-96. (PMID: 21135382)
J Neuropsychiatry Clin Neurosci. 1998 Spring;10(2):125-32. (PMID: 9608401)
J Clin Exp Neuropsychol. 2003 Jun;25(4):571-85. (PMID: 12911108)
AIDS Behav. 2019 Dec;23(12):3482-3492. (PMID: 30820848)
Arch Neurol. 1997 Apr;54(4):416-24. (PMID: 9109743)
Arch Neurol. 2007 Jan;64(1):97-102. (PMID: 17210815)
Lancet. 2008 Jul 26;372(9635):293-9. (PMID: 18657708)
AIDS Behav. 2015 Jan;19(1):166-77. (PMID: 25008384)
AIDS. 2003 Jul 4;17(10):1539-45. (PMID: 12824792)
J Int Neuropsychol Soc. 2003 Mar;9(3):419-28. (PMID: 12666766)
Neurology. 2009 Sep 1;73(9):702-8. (PMID: 19720977)
Database (Oxford). 2019 Jan 1;2019:. (PMID: 30624650)
J Neuroimmune Pharmacol. 2017 Dec;12(4):661-669. (PMID: 28470583)
معلومات مُعتمدة: U24 MH100928 United States MH NIMH NIH HHS; U24MH100925 National Institutes of Health (NIH); U24 MH100931 United States MH NIMH NIH HHS; U24 MH100930 United States MH NIMH NIH HHS
المشرفين على المادة: 0 (Anti-Retroviral Agents)
تواريخ الأحداث: Date Created: 20210213 Date Completed: 20211228 Latest Revision: 20220226
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC7881128
DOI: 10.1038/s41598-021-83131-1
PMID: 33580123
قاعدة البيانات: MEDLINE
الوصف
تدمد:2045-2322
DOI:10.1038/s41598-021-83131-1